Li Jun, Jin Junfei, Liao Minjun, Dang Wei, Chen Xinhuang, Wu Yongfeng, Liao Weijia
Laboratory of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.
Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Guilin Medical University, Guilin, Guangxi 541001, P.R. China.
Oncol Lett. 2018 Apr;15(4):4248-4254. doi: 10.3892/ol.2018.7860. Epub 2018 Jan 25.
Previous cDNA microarray experiments revealed that the ATP-dependent DNA helicase Q4 (RECQL4) gene is overexpressed in hepatocellular carcinoma (HCC) tissues. However, the exact role of RECQL4 in HCC remains unknown. The present study aimed to investigate RECQL4 expression in HCC and to analyze the potential clinical implications of RECQL4 expression in HCC patients. The expression of RECQL4 mRNA was assessed in 205 samples of HCC tissues by reverse transcription-quantitative polymerase chain reaction. The results demonstrated that the expression of RECQL4 mRNA in HCC tissues was significantly higher compared with adjacent normal liver tissues (P<0.001). The level of RECQL4 mRNA expression was associated with high a-fetoprotein (AFP) levels (>100 ng/ml), tumor size (>6 cm), and Barcelona Clinic Liver Cancer stage (all P<0.05). Kaplan-Meier survival analysis indicated that HCC patients with higher levels of RECQL4 expression exhibited significantly shorter disease-free survival (DFS) and overall survival (OS) times compared with those with low levels of expression. Multivariate survival analysis revealed that high RECQL4 expression was a significant independent predictor for DFS [HR, 1.635; 95% confidence interval (CI), 1.062-2.515; P=0.025] and OS (HR, 1.618; 95% CI, 1.050-2.493; P=0.029) of HCC patients. These data indicated that RECQL4 might be a novel diagnostic and prognostic biomarker for HCC patients.
先前的cDNA微阵列实验显示，ATP依赖的DNA解旋酶Q4（RECQL4）基因在肝细胞癌（HCC）组织中过表达。然而，RECQL4在HCC中的确切作用仍不清楚。本研究旨在调查RECQL4在HCC中的表达情况，并分析RECQL4表达在HCC患者中的潜在临床意义。通过逆转录-定量聚合酶链反应评估了205例HCC组织样本中RECQL4 mRNA的表达。结果表明，与相邻正常肝组织相比，HCC组织中RECQL4 mRNA的表达显著更高（P<0.001）。RECQL4 mRNA表达水平与高甲胎蛋白（AFP）水平（>100 ng/ml）、肿瘤大小（>6 cm）和巴塞罗那临床肝癌分期相关（均P<0.05）。Kaplan-Meier生存分析表明，与低表达水平的患者相比，RECQL4表达水平较高的HCC患者的无病生存期（DFS）和总生存期（OS）明显更短。多变量生存分析显示，高RECQL4表达是HCC患者DFS[风险比（HR），1.635；95%置信区间（CI），1.062 - 2.515；P = 0.025]和OS（HR，1.618；95% CI，1.050 - 2.493；P = 0.029）的显著独立预测因子。这些数据表明，RECQL4可能是HCC患者一种新的诊断和预后生物标志物。
